obtained are likely to be similar. As contracting with drug manufacturers is becoming more common, the two countries appear to be converging in their use of certain policy tools.
Both Australia and New Zealand review the comparative costeffectiveness of all new drugs before determining whether or not they will be subsidised. Few other countries in the world are as systematic in their application of evidence-based processes in providing access to medicines. This review process is conducted by arm's-length committees in both countries -the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia, and the Pharmacology and Therapeutics Advisory Committee in New Zealand (PTAC). A negative recommendation by these committees almost always means that the drug will not be listed (no means no), whereas a positive recommendation generally means that eventual listing will be subject to agreeable pricing terms (yes means maybe). The effect of PHARMAC's approach on medicine expenditure in New Zealand compared to Australia, Canada and the USA is striking (see Table 1 In New Zealand, there is conspicuously little evidence that limiting choices is negatively associated with health outcomes.
Limited research suggests that sweeping changes in drug availability (due to a therapeutic switching policy) may have In contrast, there is substantial evidence to suggest that the more blunt policy instrument of patient co-payments may have detrimental effects on medicine accessibility and clinical outcomes. [8] [9] [10] 'Freedom of choice' under a drug benefit program may come at considerable cost to patients when escalating program expenditures produce a 'need' for patient cost-sharing policies.
Differences in the listings of subsidised drugs between countries may be shrinking as more drugs come off patent.
Within a matter of years, virtually all of the 'blockbuster' drugs brought to market in the 1980s and 1990s will be off patent and therefore potentially available at prices that would justify unfettered subsidy -provided that the generic price is right.
Generic pricing differs quite considerably between Australia and New Zealand. Simply put, New Zealand widely uses tendering for drug products, whereas Australia does not.
In New Zealand, this limits the choice between chemically interchangeable medicines, since only one version of the generic drug is subsidised. It also dramatically reduces the cost of acquiring off-patent prescription drugs.
In the five major drug classes, 81 different drug products are subsidised by PHARMAC compared to over 650 subsidised on the PBS (Table 2 
online). Most off-patent drugs listed in New
Zealand are from sole suppliers and deep price discounts are provided in exchange for exclusivity.
A common critique of tendering processes is that sole supply of generics may result in threats to medicine availability.
While shortages are a potential risk that must be managed with tendering contracts (by including contingency and indemnity clauses), limiting national supply of an off-patent medicine to a single manufacturer is not unlike the sole supply arrangements for brand name manufacturers that are legally protected during the life of a patent.
The challenge in tipping the 'consumer choice' or 'expenditure management' scales in this debate will require a new form of social contract with retail pharmacy and, importantly,
pharmacists. This will not easily be done, but it appears to be one of the (many) objectives underlying current PBS reforms. 11 In an era of increasing generic availability, manufacturers launching new patented products into established therapeutic areas are struggling to find ways to avoid them being compared to older off-patent medicines. one way to protect a new product or class of products from this competition is to negotiate marketing contracts and pricing arrangements.
Government drug plans potentially benefit from this desire to protect new products if it allows them to list more patented products while maintaining control over costs. As the trend toward contracting evolves, policy tools in Australia and New Zealand may begin to converge. From an outsider's perspective, one might expect these two countries to emerge (again) as exemplary cases for pharmaceutical benefits management.
Building on the evidence-based coverage processes established to date, leadership in the contracting era of pharmaceutical benefits management will require reasonable transparency of the process and evidence. Since these contracts effectively result in an undisclosed lower price for government drug plans based on certain volume or bundling arrangements, agencies will have to fight to keep only the most essential components of a contract confidential and ensure clinical data are made public.
Foremost, we hope that Australia and New Zealand do not let go of the fundamental principles that set their drug benefits schemes apart from other countries -a commitment to universal benefits and the systematic application of evidencebased decision making.
* Table 2 is available online with this editorial at www.australianprescriber.com/magazine/33/1/2/4 references
